We’ll be conducting routine maintenance on Saturday, August 3rd.
Our phone system will be unavailable during this time, but you’ll be able to chat with our live agents 24/7 or you can email Support.

Mind the GLP-1 Care Gap

  • White Paper
  • Obesity care and GLP-1s

Summary

Noom’s GLP-1 Care Gap white paper delves into the health and cost risks of the GLP-1 care gap, and explores how Noom’s programs enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

Mind the GLP-1 Care Gap

The obesity epidemic in America is causing chronic conditions like type 2 diabetes, heart disease, and hypertension to rise at an alarming rate, putting significant strain on healthcare systems. While GLP-1 medications have shown impressive clinical results in treating obesity, in order for them to be effective, they must be combined with lifestyle changes.

Noom’s 2024 retrospective study on its GLP-1 Companion program highlights the benefits of this integrated approach. The findings were life-changing:

  • Average weight loss of 11.8% (28.9 lbs.) for Noom users vs. 8.5% (19.5 lbs.) for non-Noom users.
  • Medication persistence of 12.26 months for Noom users vs. 8.91 months for non-Noom users.

Noom’s GLP-1 Care Gap white paper delves into the health and cost risks of the GLP-1 care gap, and explores how Noom’s programs enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications. Personalized support and comprehensive strategies can assist members in adopting healthier habits, achieving weight loss goals, and improve health outcomes, easing the strain on health systems and offering substantial cost benefits for organizations.

Download the white paper now and explore Noom’s GLP-1 Companion program for better health outcomes and cost savings.

Download the White Paper

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • Obesity care and GLP-1s
  • May 1
  • 1 min read

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team
  • Blog
  • Obesity care and GLP-1s
  • September 5
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Jennifer Jones
  • Webinar
  • Obesity care and GLP-1s
  • May 10
  • 1 min read

Bridging the GLP-1 Care Gap for Better Outcomes and ROI

While GLP-1 medications have shown much promise for weight loss, they can leave people in worse health than before, especially when medications are not used according to the drug label: as an adjunct to a diet and exercise program.  Yet, our healthcare system isn’t well-equipped to support patients during and after a GLP-1 course of […]

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO